Javascript must be enabled to continue!
Increased Clearance Explains the Ultra-Large Multimers in Von Willebrand Disease Type 2M Vicenza; Lessons from Recombinant VWF Vicenza and Modeling of Multimer Catabolism.
View through CrossRef
Abstract
The pathogenesis of VWD Vicenza has remained elusive. VWD Vicenza is characterized by low plasma but normal platelet VWF concentration, the presence of ultra-large plasma multimers, and a heterozygous R1205H mutation. VWF Vicenza is reported to have a decreased half-life in the circulation. When we expressed rVWF Vicenza R1205H in 293T cells, it was secreted with wild type efficiency and multimer distribution, suggesting that the primary defect is accelerated clearance. To evaluate this hypothesis, we developed a pharmacokinetic model of VWF multimer catabolism. The initial assumptions are: 1. Secretion occurs at a fixed rate with the initial “ultra-large” multimer distribution seen in platelet alpha granules. 2. Cleavage of multimers occurs with a probability p that increases with increasing multimer size. 3. Clearance occurs with a time constant determined by the plasma half life and is independent of multimer size. Modeled multimer distributions were compared to those determined experimentally for patient plasma samples. The effects of DDAVP infusion also were modeled and compared to published data (Casonato et al, Blood2002; 99:180). For p = 7.5 x 10−4 min−1 and a half life of 12 h, the modeled multimer patterns were comparable to the observed steady-state distribution of normal VWF. Decreasing the half life to 2 hours produces a low plasma concentration of “ultra-large” multimers typical of VWD Vicenza without a change in any other parameter. Conversely, increasing the probability of cleavage by only thirty percent produces typical VWD 2A multimer distributions. The model also reproduces the triplet patterns of normal and type 2A VWF. Finally, the DDAVP simulations reproduced the time course of VWF plasma concentrations and multimer distributions of DDAVP-treated patients. We conclude that increased clearance alone can explain the ultra-large multimer distribution of VWD Vicenza. Similar modeling should allow the estimation of VWF cleavage and clearance rates in other variants of VWD and in other clinical situations including thrombotic thrombocytopenic purpura.
Figure Figure Figure Figure
American Society of Hematology
Title: Increased Clearance Explains the Ultra-Large Multimers in Von Willebrand Disease Type 2M Vicenza; Lessons from Recombinant VWF Vicenza and Modeling of Multimer Catabolism.
Description:
Abstract
The pathogenesis of VWD Vicenza has remained elusive.
VWD Vicenza is characterized by low plasma but normal platelet VWF concentration, the presence of ultra-large plasma multimers, and a heterozygous R1205H mutation.
VWF Vicenza is reported to have a decreased half-life in the circulation.
When we expressed rVWF Vicenza R1205H in 293T cells, it was secreted with wild type efficiency and multimer distribution, suggesting that the primary defect is accelerated clearance.
To evaluate this hypothesis, we developed a pharmacokinetic model of VWF multimer catabolism.
The initial assumptions are: 1.
Secretion occurs at a fixed rate with the initial “ultra-large” multimer distribution seen in platelet alpha granules.
2.
Cleavage of multimers occurs with a probability p that increases with increasing multimer size.
3.
Clearance occurs with a time constant determined by the plasma half life and is independent of multimer size.
Modeled multimer distributions were compared to those determined experimentally for patient plasma samples.
The effects of DDAVP infusion also were modeled and compared to published data (Casonato et al, Blood2002; 99:180).
For p = 7.
5 x 10−4 min−1 and a half life of 12 h, the modeled multimer patterns were comparable to the observed steady-state distribution of normal VWF.
Decreasing the half life to 2 hours produces a low plasma concentration of “ultra-large” multimers typical of VWD Vicenza without a change in any other parameter.
Conversely, increasing the probability of cleavage by only thirty percent produces typical VWD 2A multimer distributions.
The model also reproduces the triplet patterns of normal and type 2A VWF.
Finally, the DDAVP simulations reproduced the time course of VWF plasma concentrations and multimer distributions of DDAVP-treated patients.
We conclude that increased clearance alone can explain the ultra-large multimer distribution of VWD Vicenza.
Similar modeling should allow the estimation of VWF cleavage and clearance rates in other variants of VWD and in other clinical situations including thrombotic thrombocytopenic purpura.
Figure Figure Figure Figure.
Related Results
Laboratory Diagnosis and Molecular Classification of von Willebrand Disease
Laboratory Diagnosis and Molecular Classification of von Willebrand Disease
A complete set of laboratory investigations, including bleeding time, PFA-100 closure times, factor VIII (FVIII) coagulant activity (FVIII:C), von Willebrand factor (VWF) ristoceti...
Altered Von Willebrand Factor Subunit Proteolysis and Multimer Processing Associated with the Cys1599(2362)Phe Mutation in the B2 Domain.
Altered Von Willebrand Factor Subunit Proteolysis and Multimer Processing Associated with the Cys1599(2362)Phe Mutation in the B2 Domain.
Abstract
Cysteine residues clustered in carboxyl- and amino-terminal domains mediate the assembly of von Willebrand factor (VWF) subunits into dimers and multimers, ...
Acquired Von Willebrand Syndrome In Mitral Valve Leak
Acquired Von Willebrand Syndrome In Mitral Valve Leak
Abstract
Abstract 4657
Background
Several studies have shown that between 15% to 25% of patients with severe aort...
C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor
C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor
Summaryvon Willebrand factor (VWF) multimers result from proteolysis by the metalloprotease ADAMTS13. Since C2362F-VWF features abnormally large multimers with their triplet oligom...
The Middle and Distal Carboxyl Terminal Domains of ADAMTS13 Are Critical for Docking ADAMTS13 to von Willebrand Factor.
The Middle and Distal Carboxyl Terminal Domains of ADAMTS13 Are Critical for Docking ADAMTS13 to von Willebrand Factor.
Abstract
ADAMTS13 cleaves von Willebrand factor (VWF) at the Tyr1605-Met1606 bond of the central A2 domain. However, the domains of ADAMTS13 required for recognition...
FVIII and VWF PK: Key Aspects in Safety and Efficiency of VWF Concentrates. Review and Reflection
FVIII and VWF PK: Key Aspects in Safety and Efficiency of VWF Concentrates. Review and Reflection
Introduction: Long-term prophylaxis in Von Willebrand Disease (VWD) with a severe or frequent bleeding phenotype generates great interest. Additionally, there is a discrepancy rega...
High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC)
High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC)
Abstract
In Type I von Willebrand disease, the whole series of von Willebrand factor (vWF) multimers is present in plasma, but all are decreased in quantity. No stru...
Beta2-Glycoprotein I: Implications for a Regulatory Role in Thrombotic Thrombocytopenic Purpura.
Beta2-Glycoprotein I: Implications for a Regulatory Role in Thrombotic Thrombocytopenic Purpura.
Abstract
Introduction: Thrombotic thrombocytopenic purpura (TTP) is serologically characterized by a severe deficiency of ADAMTS-13 (von Willebrand factor (vWF)-clea...

